Lexicon Pharmaceuticals

LXRXApproved

The Woodlands, United StatesFounded 1995lexpharma.com

Lexicon Pharmaceuticals leverages its unique target discovery platform, which systematically analyzes gene function, to identify and validate novel drug targets for therapeutic development. The company achieved a significant milestone with the FDA approval of INPEFA® (sotagliflozin) for reducing cardiovascular death and hospitalization in heart failure patients. Its strategy focuses on advancing its commercial product and progressing its pipeline of internally discovered drug candidates in areas of high unmet medical need, including cardiometabolic and neuropathic disorders.

Market Cap

$660.9M

Founded

1995

Employees

100-250

Focus

BiologicsSmall Molecules

LXRX · Stock Price

USD 1.560.53 (-25.36%)

Historical price data

AI Company Overview

Technology Platform

Proprietary gene knockout technology platform that systematically inactivates individual genes in mice to study phenotypic effects and identify novel, genetically-validated drug targets for therapeutic development.

Pipeline Snapshot

49 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Telotristat etiprate	Carcinoid Syndrome	Phase 3
Sotagliflozin Low Dose + Sotagliflozin High Dose	Type 1 Diabetes (T1D)	Phase 3
Telotristat etiprate + Placebo	Carcinoid Syndrome	Phase 3
Sotagliflozin + Placebo	Obstructive Cardiomyopathy, Hypertrophic	Phase 3
Telotristat etiprate + Placebo-matching telotristat etiprate	Carcinoid Syndrome	Phase 3

FDA Approved Drugs

INPEFANDAMay 26, 2023

Opportunities

The primary growth opportunity is the successful commercial launch and market penetration of INPEFA in the large heart failure market.

Positive Phase 2 data for LX9211 could unlock a second major opportunity in the multi-billion dollar neuropathic pain market, either through internal development or a lucrative partnership.

The gene knockout platform also provides a long-term opportunity for discovering additional novel drug candidates.

Risk Factors

Key risks include commercial failure of INPEFA against established competitors, negative clinical trial results for LX9211, continued financial losses requiring dilutive financing, and high dependency on a narrow pipeline.

Execution risk in building a successful sales and marketing organization is significant.

Competitive Landscape

INPEFA competes directly with established SGLT2 inhibitors (Jardiance, Farxiga) in heart failure, marketed by large pharmaceutical companies with greater resources. LX9211, if successful, would compete in neuropathic pain against both generic standards of care and newer branded agents. Lexicon's differentiation is its novel, genetically-validated drug targets and first-in-class mechanisms.

Publications

Patents

Pipeline

FDA Approvals